Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Munker, D; Arnold, P; Veit, T; Leuschner, G; Ceelen, F; Barnikel, M; Schmitzer, M; Barton, J; Sonneck, T; Milger, K; Matthes, S; Schiopu, S; Kauke, T; Weig, T; Kneidinger, N; Behr, J; Neurohr, C.
Safety and Efficacy of Steroid Pulse Therapy for Acute Loss of FEV₁ in Lung Transplant Recipients After Exclusion of Acute Cellular Rejection.
Transplant Proc. 2020; 52(1):309-314 Doi: 10.1016/j.transproceed.2019.10.013
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Kneidinger Nikolaus; Milger-Kneidinger Katrin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: The standard treatment of acute cellular rejection after lung transplantation (LTx) is a high-dose steroid pulse therapy. In our center, this therapy is also the standard of care for LTx recipients with acute loss of forced expiratory volume in 1 second (FEV₁), after excluding specific causes such as acute rejection on biopsy. The aim of this retrospective study was to evaluate the safety and efficacy of steroid pulse therapy. METHODS: From 2015 to 2018, 33 consecutive patients (17 male patients, mean age ± SD, 50.5 ± 12.5 years) were included. All patients underwent routine examinations to exclude acute cellular rejection and other specific causes. FEV₁ was routinely measured after 5 days, and 1, 3, and 6 months. Positive response to steroid pulse therapy was defined by increase of FEV₁ > 10%. RESULTS: The mean decrease ± SD from baseline in FEV₁ at the start of steroid pulse therapy was 380 ± 630 mL (P = .02). FEV₁ changed after 5 days by 170 ± 180 mL (P = .0007), and after 1 month by 140 ± 230 mL (P = .70), 3 months by -60 ± 240 mL (P = .15), and 6 months by -80 ± 290 mL (P = .73). A positive response was observed in 21% of patients after 3 months and 12% after 6 months. High bronchoalveolar lavage (BAL) eosinophil count correlated with a higher FEV₁ after steroid pulse therapy. Serious complications were observed in 4 out of 33 patients (12%) with 1 fatal event (pneumonia). CONCLUSIONS: Only a minority of patients after LTx with loss of FEV₁ after exclusion of acute cellular rejection benefit from steroid pulse therapy. Patients with BAL eosinophilia are more likely to respond. However, severe complications were observed.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; Bronchiolitis Obliterans - diet therapy, etiology; Female - administration & dosage; Glucocorticoids - administration & dosage; Graft Rejection - drug therapy, pathology; Humans - administration & dosage; Lung Transplantation - adverse effects; Male - administration & dosage; Middle Aged - administration & dosage; Prednisone - administration & dosage; Retrospective Studies - administration & dosage; Transplant Recipients - administration & dosage